|Description||(-)-Terreic acid is a selective inhibitor of Bruton's tyrosine kinase (BTK) with antibiotic activity. (-)-Terreic acid inhibits the catalytic activity of BTK and suppresses the interaction between PKCbII and BTK (IC50 ~ 30 mM).|
|Brife Description||BTK inhibitor|
|Purity||≥99% by HPLC|
|Synonyms||(1R,6S)-3-Hydroxy-4-methyl-7-oxabicyclo[4.1.0]hept-3-ene-2,5-dione; Terreic Acid; 5,6-Epoxy-3-hydroxy-p-toluquinone|
ONO-4059, a BTK inhibitor, has been found to have potential effect against sorts of malignancies by influencing the B-cell development. It is currently under Ph...
(-)-Terreic acid is a selective inhibitor of Bruton's tyrosine kinase (BTK) with antibiotic activity. (-)-Terreic acid inhibits the catalytic activity of BTK an...
ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.
Potent BTK inhibitor (IC50 = 0.3 nM). Blocks B cell antigen receptor (BCR)-mediated gene expression in CD20+ B cells.
GDC-0834 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis. In vitro metabol...
Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. It inhibits the...
BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability, achieving higher ...
Olmutinib, also called as HM61713 and BI-1482694, is an orally available, mutant-selective third-generation epidermal growth factor receptor tyrosine kinase inh...